Trial Profile
A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications CNS disorders; Multiple sclerosis; Peripheral nerve injuries; Spinal cord disorders
- Focus Adverse reactions; Registrational
- Sponsors Jazz Pharmaceuticals Inc
- 20 Apr 2015 New trial record